Label: SALKALLI- retatrutide lyophilized powder injection, powder, lyophilized, for solution
-
Contains inactivated NDC Code(s)
NDC Code(s): 84778-110-05, 84778-110-06, 84778-110-07, 84778-110-08 - Packager: Guangzhou Yixin Cross-border E-commerce Co., Ltd.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Export only
Drug Label Information
Updated November 7, 2025
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- Active ingredients (in each kit)
- Purpose
- Uses
-
Warnings — Read carefully and tell your doctor if any apply to you.
Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
Pregnancy or breastfeeding: Do not use.
Children: Do not use.Drug Interactions / Precautions
Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
Possible side effects
Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.
When to stop and call your doctor
If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.
-
Directions — Preparation & Dosing (basic patient summary)
Concentration after reconstitution (calculation):
10 mg ÷ 1 mL = 10 mg/mL.
Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.Typical weekly dosing schedule (example shown — follow your prescriber):
Weeks 1–4: 0.25 mL (2.5 mg) once weekly (subcutaneous)
Weeks 5–8: 0.5 mL (5 mg) once weekly
Weeks 9–12: 0.75 mL (7.5 mg) once weekly
Week 13 and onward: 1 mL (10 mg) once weeklyOne carton (4 kits) provides 4 weekly doses.
How to prepare and inject (patient summary):
Wash hands with soap and water. Inspect vials for damage.
Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.
Gently swirl the vial until the powder fully dissolves. Do not shake vigorously. Solution should be clear; do not use if cloudy or particulate present.
Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.
Dispose of syringe/needle in an appropriate sharps container. -
Do not use
Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
-
When using section
Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
Pregnancy or breastfeeding: Do not use.
Children: Do not use.Drug Interactions / Precautions
Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
Possible side effects
Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.
When to stop and call your doctor
If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.
-
stop use
Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
Pregnancy or breastfeeding: Do not use.
Children: Do not use.Drug Interactions / Precautions
Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
Possible side effects
Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.
When to stop and call your doctor
If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.
- Keep out of reach of children.
- Inactive Ingredients:
- PRINCIPAL DISPLAY PANEL
-
INGREDIENTS AND APPEARANCE
SALKALLI
retatrutide lyophilized powder injection, powder, lyophilized, for solutionProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:84778-110 Route of Administration SUBCUTANEOUS Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV) RETATRUTIDE 2.5 mg in 0.25 mL Inactive Ingredients Ingredient Name Strength SODIUM BICARBONATE (UNII: 8MDF5V39QO) MANNITOL (UNII: 3OWL53L36A) SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW) SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F) SODIUM CHLORIDE (UNII: 451W47IQ8X) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:84778-110-06 2 in 1 PACKAGE, COMBINATION 10/30/2025 1 4 in 1 CARTON 1 0.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package 2 NDC:84778-110-05 4 in 1 CARTON 10/30/2025 2 0.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package 3 NDC:84778-110-07 3 in 1 PACKAGE, COMBINATION 10/30/2025 3 4 in 1 CARTON 3 0.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package 4 NDC:84778-110-08 4 in 1 PACKAGE, COMBINATION 10/30/2025 4 4 in 1 CARTON 4 0.25 mL in 1 KIT; Type 1: Convenience Kit of Co-Package Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Export only 10/30/2025 Labeler - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881) Registrant - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881) Establishment Name Address ID/FEI Business Operations Guangzhou Yixin Cross-border E-commerce Co., Ltd. 455800881 label(84778-110) , manufacture(84778-110)




